EA201201585A1 - ANTI-TUMOR MEDICINE (OPTIONS) - Google Patents
ANTI-TUMOR MEDICINE (OPTIONS)Info
- Publication number
- EA201201585A1 EA201201585A1 EA201201585A EA201201585A EA201201585A1 EA 201201585 A1 EA201201585 A1 EA 201201585A1 EA 201201585 A EA201201585 A EA 201201585A EA 201201585 A EA201201585 A EA 201201585A EA 201201585 A1 EA201201585 A1 EA 201201585A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bortezomib
- creation
- antitumor agent
- isotopes
- increase
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении противоопухолевых средств, в частности ингибиторов протеасом на основе бортезомиба. Задачей настоящего изобретения является создание эффективного противоопухолевого средства на базе бортезомиба с расширенными свойствами при использовании. Задача решается за счет того, что противоопухолевое средство содержит бортезомиб, минеральные вещества натрий, кальций, изотопы углеродаС, изотопы азотаN. Техническими результатами изобретения являются увеличение лечебного эффекта без увеличения концентрации бортезомиба при лечении злокачественных опухолей за счет использования в противоопухолевом средстве изотоповС,N и минеральных веществ; увеличение времени хранения, в том числе в готовом к применению жидком виде.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and application of anticancer drugs, in particular bortezomiba-based proteasome inhibitors. The present invention is the creation of an effective anticancer agent on the basis of bortezomib with enhanced properties during use. The problem is solved due to the fact that the antitumor agent contains bortezomib, mineral substances sodium, calcium, carbon isotopes, nitrogen isotopesN. Technical results of the invention are to increase the therapeutic effect without increasing the concentration of bortezomib in the treatment of malignant tumors due to the use in the antitumor agent isotopes C, N and minerals; increase storage time, including in ready-to-use liquid form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201585A EA201201585A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201201585A EA201201585A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201201585A1 true EA201201585A1 (en) | 2014-06-30 |
Family
ID=51013723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201585A EA201201585A1 (en) | 2012-12-24 | 2012-12-24 | ANTI-TUMOR MEDICINE (OPTIONS) |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA201201585A1 (en) |
-
2012
- 2012-12-24 EA EA201201585A patent/EA201201585A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691059A1 (en) | PEPTIDOMYMETICS COMPOUNDS AND THEIR CONJUGATES CONTAINING ANTIBODY AND MEDICINE | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| EA201691023A1 (en) | PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE | |
| TR201807411T4 (en) | DNA-PK inhibitors. | |
| MX2021007651A (en) | Ezh2 inhibitors for treating lymphoma. | |
| EA201591925A1 (en) | THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION | |
| MX2018016332A (en) | Combination chemotherapies. | |
| PH12016501554A1 (en) | Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug | |
| EA201201654A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201585A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201584A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201616A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201588A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201589A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201587A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201590A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201586A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA201201655A1 (en) | ANTI-TUMOR MEDICINE (OPTIONS) | |
| EA202190294A1 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| EA202190291A1 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| RU2012115039A (en) | METHOD FOR TREATING CHRONIC ENDOMETRITIS | |
| EA201300373A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| EA201300370A1 (en) | ANTIOXIDANT PHARMACEUTICAL COMPOSITION (OPTIONS) | |
| RU2014146031A (en) | Pharmaceutical gel based on doxorubicin and organosilicon niosomes-niosomes for the treatment of skin cancer | |
| EA201992500A2 (en) | Salts and Drugs of 1-Methyl-D-Tryptophan |